INSURICA Employee Benefits Insights
Keeping you ahead of the risks and challenges unique to your industry.
November 2022
“According to the Kaiser Family Foundation, approximately 156,199,800 Americans receive health benefits via employer-sponsored plans.
FEATURED ARTICLE
President Joe Biden signed the Inflation Reduction Act (IRA) into law on August 16, following House and Senate passage.
FEATURED ARTICLE
According to the Kaiser Family Foundation, approximately 156,199,800 Americans receive health benefits via employer-sponsored plans.
FEATURED ARTICLE
As healthcare benefits costs continue to rise, 67% of U.S. employers are focused on cost control over the next three years. This is in response to an expected 6% increase in healthcare costs in 2023, compared to the average 5% increase this year.
FEATURED ARTICLE
Health benefits are a top priority for most employers, but hearing health is often overlooked.
Related Articles
Fiduciary Responsibilities for Employer Health Plans: What Employers Should Know Now
When employers think about fiduciary responsibility, retirement plans often come to mind first. But recent developments make it clear that fiduciary duties also matter—sometimes significantly—when it comes to employer-sponsored health and welfare plans.
The New Era of Mental Health Parity Enforcement in 2026
Federal agencies have made mental health parity enforcement a top priority in 2026, and employers sponsoring group health plans are feeling the impact. Regulators are no longer satisfied with high‑level assurances that plans comply with the Mental Health Parity and Addiction Equity Act (MHPAEA). Instead, they expect detailed, data‑driven documentation showing that mental health and substance‑use‑disorder benefits are truly comparable to medical and surgical benefits. This includes not only the written plan design but also how rules are applied in real‑world scenarios.
The 2026 Specialty Drug Surge: What Employers Need to Prepare For
Specialty drugs have been a major cost driver for years, but 2026 marks a significant shift in both scale and urgency. With GLP 1 medications expanding into new indications, gene therapies entering the market at record pace, and oncology drugs continuing to rise in both cost and utilization, specialty medications are projected to account for more than 60% of total pharmacy spending this year. That’s a dramatic change for employers, especially considering that specialty drugs represent fewer than 5% of total prescriptions.